vs

Side-by-side financial comparison of BOSTON OMAHA Corp (BOC) and Strata Critical Medical, Inc. (SRTA). Click either name above to swap in a different company.

BOSTON OMAHA Corp is the larger business by last-quarter revenue ($29.7M vs $22.7M, roughly 1.3× Strata Critical Medical, Inc.). On growth, Strata Critical Medical, Inc. posted the faster year-over-year revenue change (361.2% vs 6.4%). BOSTON OMAHA Corp produced more free cash flow last quarter ($-10.0M vs $-10.2M). Over the past eight quarters, BOSTON OMAHA Corp's revenue compounded faster (7.8% CAGR vs -33.6%).

Boston Omaha Corporation is a publicly traded diversified holding company. Its core operating segments include outdoor advertising, surety insurance, residential real estate development, and fixed wireless broadband services, primarily serving customers across the United States, with a focus on driving long-term shareholder value via strategic acquisitions and organic operational growth.

Strata Critical Medical, Inc. is a medical technology firm designing, producing and distributing disposable medical products for critical care, anesthesia and surgical use cases. It serves healthcare providers across North America and some European markets, focusing on improving patient safety and clinical efficiency.

BOC vs SRTA — Head-to-Head

Bigger by revenue
BOC
BOC
1.3× larger
BOC
$29.7M
$22.7M
SRTA
Growing faster (revenue YoY)
SRTA
SRTA
+354.9% gap
SRTA
361.2%
6.4%
BOC
More free cash flow
BOC
BOC
$114.3K more FCF
BOC
$-10.0M
$-10.2M
SRTA
Faster 2-yr revenue CAGR
BOC
BOC
Annualised
BOC
7.8%
-33.6%
SRTA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BOC
BOC
SRTA
SRTA
Revenue
$29.7M
$22.7M
Net Profit
$-6.9M
Gross Margin
64.0%
-0.9%
Operating Margin
-4.2%
-18.4%
Net Margin
-23.1%
Revenue YoY
6.4%
361.2%
Net Profit YoY
-228.1%
EPS (diluted)
$-0.23
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BOC
BOC
SRTA
SRTA
Q4 25
$29.7M
$22.7M
Q3 25
$28.7M
$49.3M
Q2 25
$28.2M
$70.8M
Q1 25
$27.7M
$54.3M
Q4 24
$27.9M
$-8.7M
Q3 24
$27.7M
$36.1M
Q2 24
$27.1M
$67.9M
Q1 24
$25.6M
$51.5M
Net Profit
BOC
BOC
SRTA
SRTA
Q4 25
$-6.9M
Q3 25
$-2.6M
$57.4M
Q2 25
$-2.3M
$-3.7M
Q1 25
$-669.3K
$-3.5M
Q4 24
$5.3M
Q3 24
$-1.6M
$-2.0M
Q2 24
$-2.2M
$-11.3M
Q1 24
$-2.8M
$-4.2M
Gross Margin
BOC
BOC
SRTA
SRTA
Q4 25
64.0%
-0.9%
Q3 25
66.2%
23.6%
Q2 25
66.1%
25.1%
Q1 25
67.3%
22.1%
Q4 24
69.5%
Q3 24
67.5%
20.8%
Q2 24
68.2%
24.1%
Q1 24
67.9%
19.7%
Operating Margin
BOC
BOC
SRTA
SRTA
Q4 25
-4.2%
-18.4%
Q3 25
-3.7%
-11.4%
Q2 25
-2.9%
-7.0%
Q1 25
-2.9%
-14.0%
Q4 24
-4.6%
Q3 24
-2.7%
-19.7%
Q2 24
-16.2%
-17.9%
Q1 24
-8.1%
-19.2%
Net Margin
BOC
BOC
SRTA
SRTA
Q4 25
-23.1%
Q3 25
-9.0%
116.5%
Q2 25
-8.2%
-5.3%
Q1 25
-2.4%
-6.4%
Q4 24
19.1%
Q3 24
-5.8%
-5.4%
Q2 24
-8.3%
-16.7%
Q1 24
-11.0%
-8.2%
EPS (diluted)
BOC
BOC
SRTA
SRTA
Q4 25
$-0.23
$-0.11
Q3 25
$-0.08
$0.70
Q2 25
$-0.07
$-0.05
Q1 25
$-0.02
$-0.04
Q4 24
$0.17
$-0.11
Q3 24
$-0.05
$-0.03
Q2 24
$-0.07
$-0.15
Q1 24
$-0.09
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BOC
BOC
SRTA
SRTA
Cash + ST InvestmentsLiquidity on hand
$56.8M
$31.0M
Total DebtLower is stronger
$25.7M
Stockholders' EquityBook value
$516.1M
$279.1M
Total Assets
$713.1M
$325.5M
Debt / EquityLower = less leverage
0.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BOC
BOC
SRTA
SRTA
Q4 25
$56.8M
$31.0M
Q3 25
$67.6M
$22.8M
Q2 25
$68.6M
$58.8M
Q1 25
$69.2M
$34.8M
Q4 24
$73.2M
$18.4M
Q3 24
$58.6M
$20.0M
Q2 24
$53.1M
$26.3M
Q1 24
$53.4M
$36.8M
Total Debt
BOC
BOC
SRTA
SRTA
Q4 25
$25.7M
Q3 25
$25.9M
Q2 25
$26.1M
Q1 25
$26.3M
Q4 24
$26.5M
Q3 24
$26.7M
Q2 24
$26.9M
Q1 24
$27.1M
Stockholders' Equity
BOC
BOC
SRTA
SRTA
Q4 25
$516.1M
$279.1M
Q3 25
$528.4M
$283.0M
Q2 25
$531.0M
$223.1M
Q1 25
$533.3M
$219.7M
Q4 24
$532.8M
$221.9M
Q3 24
$527.7M
$233.5M
Q2 24
$530.5M
$229.4M
Q1 24
$536.2M
$236.6M
Total Assets
BOC
BOC
SRTA
SRTA
Q4 25
$713.1M
$325.5M
Q3 25
$721.4M
$335.1M
Q2 25
$730.6M
$257.9M
Q1 25
$730.8M
$250.6M
Q4 24
$728.3M
$256.7M
Q3 24
$711.9M
$282.9M
Q2 24
$723.1M
$280.3M
Q1 24
$757.3M
$282.8M
Debt / Equity
BOC
BOC
SRTA
SRTA
Q4 25
0.05×
Q3 25
0.05×
Q2 25
0.05×
Q1 25
0.05×
Q4 24
0.05×
Q3 24
0.05×
Q2 24
0.05×
Q1 24
0.05×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BOC
BOC
SRTA
SRTA
Operating Cash FlowLast quarter
$17.9M
$-8.3M
Free Cash FlowOCF − Capex
$-10.0M
$-10.2M
FCF MarginFCF / Revenue
-33.8%
-44.7%
Capex IntensityCapex / Revenue
93.9%
8.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-17.6M
$-58.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BOC
BOC
SRTA
SRTA
Q4 25
$17.9M
$-8.3M
Q3 25
$4.9M
$-37.3M
Q2 25
$4.6M
$-3.1M
Q1 25
$2.6M
$-246.0K
Q4 24
$21.2M
$-1.8M
Q3 24
$5.2M
$6.4M
Q2 24
$4.5M
$8.4M
Q1 24
$2.4M
$-15.6M
Free Cash Flow
BOC
BOC
SRTA
SRTA
Q4 25
$-10.0M
$-10.2M
Q3 25
$-489.4K
$-40.1M
Q2 25
$-2.7M
$-5.4M
Q1 25
$-4.3M
$-2.9M
Q4 24
$-11.0M
$-6.3M
Q3 24
$-1.2M
$-3.0M
Q2 24
$-4.3M
$-7.7M
Q1 24
$-6.0M
$-16.4M
FCF Margin
BOC
BOC
SRTA
SRTA
Q4 25
-33.8%
-44.7%
Q3 25
-1.7%
-81.4%
Q2 25
-9.7%
-7.6%
Q1 25
-15.5%
-5.3%
Q4 24
-39.2%
72.7%
Q3 24
-4.4%
-8.2%
Q2 24
-15.9%
-11.4%
Q1 24
-23.6%
-31.8%
Capex Intensity
BOC
BOC
SRTA
SRTA
Q4 25
93.9%
8.1%
Q3 25
18.9%
5.7%
Q2 25
25.9%
3.2%
Q1 25
24.7%
4.8%
Q4 24
115.3%
-52.6%
Q3 24
23.2%
25.8%
Q2 24
32.6%
23.8%
Q1 24
33.1%
1.6%
Cash Conversion
BOC
BOC
SRTA
SRTA
Q4 25
Q3 25
-0.65×
Q2 25
Q1 25
Q4 24
3.97×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BOC
BOC

Billboard Rentals$11.9M40%
Equity Method Investment Nonconsolidated Investee Or Group Of Investees$10.0M34%
GIG$7.3M25%
Other$608.4K2%

SRTA
SRTA

Other Clinical$11.4M50%
Transplant Clinical$9.0M39%
Other$2.4M11%

Related Comparisons